Allogeneic human umbilical cord blood haematopoietic progenitor cell therapy(StemCyte)

异基因人脐带血造血祖细胞疗法（美商永生）

Report date: 2026/03/31 20:00:21

Base Information

Drug NameAllogeneic human umbilical cord blood haematopoietic progenitor cell therapy(StemCyte)
Drug Alias NameHPC cord blood(StemCyte)REGENECYTE
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeHematopoietic stem cell transplantation (HSCT)
Global Approved IndicationsHematopoietic stem cell transplantation (HSCT)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/11/20
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesStemcyte Inc
China Registration ClassN/A

Develop Information

Active CompaniesStemcyte Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeHematopoietic stem cell transplantation (HSCT)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A